Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00754494
Other study ID # NCI-2012-02984
Secondary ID UCI06-8-01N01CN3
Status Completed
Phase Phase 2
First received September 17, 2008
Last updated December 22, 2014
Start date July 2008
Est. completion date September 2013

Study information

Verified date March 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase II trial is studying how well erlotinib hydrochloride works in treating patients with stage I-III colorectal cancer or adenoma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Erlotinib hydrochloride may also stop tumors from growing or coming back


Description:

PRIMARY OBJECTIVES:

I. To test the hypothesis that erlotinib (erlotinib hydrochloride) doses as low as 25 mg will decrease aberrant crypt foci (ACF) phosphorylated extracellular signal-regulated kinases (pERK) levels from baseline (pre) to post erlotinib treatment.

SECONDARY OBJECTIVES:

I. To test the hypothesis that additional epidermal growth factor (EGF) inducible biomarkers will decrease from baseline (pre) to post treatment with erlotinib 25 mg, 50 mg or 100 mg orally (PO) once daily (QD) therapy.

II. To determine the mean decrease from baseline of the ACF: normal mucosa pERK ratio pre and post 8-30 days of erlotinib.

III. To determine erlotinib concentration in plasma and colorectal tissue at 25 mg, 50 mg and 100 mg doses after 8-30 days of therapy.

IV. To determine the incidence of rash, diarrhea and other side effects of low dose erlotinib.

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM I: Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.

ARM II: Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.

ARM III: Patients receive 25 mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.

In all arms, treatment continues for 8-30 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 to 9 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date September 2013
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants with one or more of the following criteria will be eligible to participate:

- History of Stage I-III colorectal cancer, not treated in the past 6 months with no anticipated treatment in the next 3 months

- Adenoma = 1 cm in size

- 3 or more adenomas (of any size) removed at one colonoscopy within past 6 years

- Sessile serrated adenoma = 5 mm in size

- Adenoma (of any size) with villous features (villous, tubulovillous)

- Adenoma (of any size) with high grade dysplasia

- Participants are eligible for randomization into the treatment phase of the trial if they are found to have = 4 ACFs at either baseline colonoscopy or baseline flexible sigmoidoscopy

- Blood tests at screening which meet the following criteria:

- WBC > 3000/mm^3

- Platelets > 100,000/mm^3

- Hemoglobin > 10g/dl

- Plasma creatinine of < 1.6mg/dl

- Total bilirubin < 1.5 x the upper limit of normal

- Serum ALT < 1.5 x the upper limit of normal

- Serum AST < 1.5 x the upper limit of normal

- ECOG performance status 0-1

- Women of child-bearing potential and men taking study drug must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

- Ability to understand, as well as sign the written informed consent document

- If a woman is of child-bearing potential, she must have a negative pregnancy test prior to study entry; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

Exclusion Criteria:

- History of Inflammatory Bowel Disease (IBD)

- History of interstitial lung disease or chronic lung disease

- Smoking within the past 3 months

- Increased bleeding risk from rectal biopsy (Patients receiving aspirin or plavix can be enrolled)

- Patients receiving warfarin or coumadin

- Uncontrollable diarrhea of any cause

- Patients, including rectal cancer patients, that have received prior radiation to the rectum or pelvis

- Participants taking a known significant CYP 3A4 inducer or inhibitor; known significant inducers/inhibitors include: amprenavir, aprepitant, atazanavir, carbamazepine, clarithromycin, conivaptan, diltiazem, darunavir/ritonavir, dronedarone, erythromycin, fluconazole, fosamprenavir, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, phenytoin, posaconazole, rifampin, ritonavir, St. John's wort, saquinavir, telithromycin, tipranavir/ritonavir, verapamil, voriconazole

- Women who are pregnant or breast-feeding

- Active keratoconjunctivitis, or corneal surgery in the past three weeks

- Any medical or psychosocial condition that could jeopardize the subject's participation in and compliance to the study

- Participants who are taking any other investigational pharmaceutical agents

- Previous history of sensitivity to erlotinib, Iressa, or Erbitux, such as a rash that is uncontrollable by topical steroids and/or antibiotics

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Intervention

Drug:
erlotinib hydrochloride
Given PO
Other:
placebo
Given PO
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States University of Illinois at Chicago Chicago Illinois
United States VA Long Beach Healthcare System Long Beach California
United States Chao Family Comprehensive Cancer Center Orange California

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in ACF pERK Levels Quantification will be performed by Western blot analysis. Tested using paired t-test with a two-sided significance level of 0.05. From baseline to post-treatment (up to 30 days) No
Secondary Change in EGF-inducible Markers - pEGFR in Normal Mucosa pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported. From baseline to post-treatment (up to 30 days) No
Secondary Change in EGF-inducible Markers - Total EGFR in Normal Mucosa Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported. From baseline to post-treatment (up to 30 days) No
Secondary Change in EGF-inducible Markers - pEGFR in ACF pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported. From baseline to post-treatment (up to 30 days) No
Secondary Change in EGF-inducible Markers - Total EGFR in ACF Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported. From baseline to post-treatment (up to 30 days) No
Secondary ACF: Normal Mucosa pERK Ratio Quantification will be performed by Western blot analysis. Tested using analysis of variance with subsequent pairwise comparisons using the Tukey method to adjust for multiple comparisons. Up to day 30 No
Secondary Plasma Erlotinib Concentration (ng/mL) Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations). Up to day 30 No
Secondary Plasma OSI-420 Concentration (ng/mL) Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations). Up to day 30 No
Secondary Normal Mucosa Erlotinib Concentration (ng/mg) Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations). Up to day 30 No
Secondary Normal Mucosa OSI-420 Concentration (ng/mg) Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations). Up to day 30 No
Secondary Number of Participants Reported at Least 1 Side Effect During the Study Described for each arm using frequencies. The onset of adverse events is between randomization date and off-study date. Up to 9 weeks Yes
Secondary Number of Participants Reported at Least 1 Rash Side Effect During the Study Described for each arm using frequencies. Up to 9 weeks Yes
Secondary Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study Described for each arm using frequencies. Up to 9 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT01987726 - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Active, not recruiting NCT00826540 - Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT00025337 - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Phase 3
Recruiting NCT04642924 - SGM-101 in Locally Advanced and Recurrent Rectal Cancer Phase 2/Phase 3
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01217450 - Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors Phase 1
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01238965 - Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy Phase 1
Terminated NCT01285102 - Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00551421 - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT00407654 - VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Terminated NCT00052585 - Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer Phase 2
Completed NCT00023933 - Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer Phase 1
Not yet recruiting NCT05076305 - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Completed NCT01740648 - Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Phase 1
Terminated NCT00397878 - AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer Phase 2
Completed NCT00100841 - Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Phase 2